Department of Clinical Oncology, Clinical Hospital, University of Uruguay, Avda. Italia s/n, Montevideo, Uruguay.
Breast Cancer Res Treat. 2011 Jul;128(1):211-8. doi: 10.1007/s10549-010-1320-2. Epub 2010 Dec 29.
The aim of the present study was to analyze BRCA1 and BRCA2 mutations in Uruguayan families with breast and breast/ovarian cancer. Probands from 42 families with at least three cases of female breast cancer (BC) or two cases and subcriteria (paternal transmission, ovarian cancer, bilateral BC, male BC, Ashkenazi Jewish ancestry) in the same lineage, at least one diagnosed before age 50, were screened for germline mutations. PCR amplification of all exons and intron-exon boundaries were performed, followed by protein truncation test, heteroduplex analysis, and direct sequencing. We identified seven different truncating mutations in seven families, five in BRCA2 (three in site-specific BC families and two in breast-ovarian cancer families) and two in BRCA1 (one in a site-specific BC family and the other in a breast-ovarian cancer family). Both BRCA1 mutations (5583insT and 2687T>G) and one of the five BRCA2 mutations (3829insTdel35) were not previously reported. We also detected ten sequence variants of unknown significance, five of them not described before. The low frequency of BRCA1/2 mutations (0.17) is in agreement with that reported in studies which included families with similar selection criteria. However, the observed predominance of BRCA2 (0.12) over BRCA1 mutations (0.05) is in contrast with the higher proportion of BRCA1 mutations communicated for most previous studies, even those with a predominance of site-specific BC families. Meanwhile, it has been described in one Chilean and some Spanish and Italian reports, highlighting the strong dependence between the mutational spectra and the ethnicity of the population analyzed.
本研究旨在分析乌拉圭乳腺癌和乳腺癌/卵巢癌家系中的 BRCA1 和 BRCA2 突变。从 42 个家系中筛选出至少有 3 例女性乳腺癌(BC)或 2 例且符合亚标准(父系传递、卵巢癌、双侧 BC、男性 BC、阿什肯纳兹犹太血统)的先证者,至少有 1 例在 50 岁前确诊,对其进行种系突变筛查。对所有外显子和内含子-外显子边界进行 PCR 扩增,然后进行蛋白截断试验、异源双链分析和直接测序。我们在 7 个家系中发现了 7 种不同的截断突变,其中 5 种在 BRCA2 中(3 种在特定部位 BC 家系中,2 种在乳腺癌-卵巢癌家系中),2 种在 BRCA1 中(1 种在特定部位 BC 家系中,另一种在乳腺癌-卵巢癌家系中)。两个 BRCA1 突变(5583insT 和 2687T>G)和 5 个 BRCA2 突变中的一个(3829insTdel35)以前没有报道过。我们还检测到 10 个未知意义的序列变异,其中 5 个以前没有描述过。BRCA1/2 突变的低频率(0.17)与包括具有类似选择标准的家系的研究中报道的频率一致。然而,BRCA2 突变(0.12)的优势高于 BRCA1 突变(0.05),这与大多数先前研究报告的 BRCA1 突变比例较高形成对比,甚至与那些以特定部位 BC 家系为主的研究也是如此。同时,在一个智利和一些西班牙和意大利的报告中也有描述,这突出了突变谱与所分析人群的种族之间的强烈依赖性。